Several agents including PI3K inhibitor (LY294002) or AKT inhibitor (MK2206) have been demonstrated alone or in combinations with DNA-targeted drugs (gemcitabine and 5-fluorouracil) in pancreatic cancer [34, 50]. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.